PATENT CLAIM ANALYSIS

Application Number: 15780850
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "289000"]

Abstract:
The invention relates to dextrorphan-derivatives, pharmaceutical compositions and pharmaceutical dosage forms containing such dextrorphan-derivatives as well as the use of those dextrorphan-derivatives and/or compositions for treating and preventing diseases and conditions in man and mammals.

Claim (Index 13):
The dextrorphan-derivative according to  claim 1 , which is selected from the group consisting of:\n (+)-2-amino-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan-3-ol; (+)-2-amino-3-methoxy-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan; (+)-2-amino-3-methyl-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan; (+)-2-methylamino-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan-3-ol; (+)-2-methylamino-3-methoxy-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan; (+)-2-methylamino-3-methyl-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan; (+)-2,2-dimethylamino-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan-3-ol; (+)-2,2-dimethylamino-3-methoxy-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan; (+)-2,2-dimethylamino-3-methyl-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan; (+)-2-ethylamino-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan-3-ol; (+)-2-ethylamino-3-methoxy-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan; (+)-2-ethylamino-3-methyl-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan; (+)-2-(2-fluoro-ethyl)amino-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan-3-ol; (+)-2-(2-fluoro-ethyl)amino-3-methoxy-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan; (+)-2-(2-fluoro-ethyl)amino-3-methyl-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan; (+)-2-(2,2-difluoro-ethyl)amino-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan-3-ol; (+)-2-(2,2-difluoro-ethyl)amino-3-methoxy-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan; (+)-2-(2,2-difluoro-ethyl)amino-3-methyl-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan; (+)-2-iodo-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan-3-ol; (+)-2-iodo-3-methoxy-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan; (+)-2-iodo-3-methyl-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan; (+)-2-(1-pyrrolidyl)-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan-3-ol; (+)-2-(1-pyrrolidyl)-3-methoxy-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan; (+)-2-(1-pyrrolidyl)-3-methyl-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan; (+)-2-(1-imidazolyl)-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan-3-ol; (+)-2-(1-imidazolyl)-3-methoxy-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan; (+)-2-(1-imidazolyl)-3-methyl-17-methyl-9\u03b1,13\u03b1,14\u03b1-morphinan; or a physiologically acceptable salt thereof.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 94.0
- Lexical Diversity: 1.27586
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14241131', '11361589', '15068404', '11836159', '14208968']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7950422080861599
- 35 USC 102 Novelty (BERT): 0.5317417815479295
- Combined Prediction Score: 0.7687121654323369
- Mean Citation Score: 272.22389400000003
- Max Citation Score: 359.0168
- Similarity Product: 225.2569128809929

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test